

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 471/04, A61K 31/44 // (C07D 471/04, 221:00, 221:00)	A1	(11) International Publication Number: WO 99/58533 (43) International Publication Date: 18 November 1999 (18.11.99)
(21) International Application Number: PCT/EP99/03100 (22) International Filing Date: 4 May 1999 (04.05.99) (30) Priority Data: 9809972.4 8 May 1998 (08.05.98) GB 9809988.0 8 May 1998 (08.05.98) GB 9903268.2 12 February 1999 (12.02.99) GB (71) Applicant (for all designated States except US): SMITHKLINE BEECHAM PLC [GB/GB]; New Horizons Court, Brentford, Middlesex TW8 9EP (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): JOHNS, Amanda [GB/GB]; SmithKline Beecham Pharmaceuticals, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB). PORTER, Roderick, Alan [GB/GB]; SmithKline Beecham Pharmaceuticals, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB). (74) Agent: BLAKEY, Alison, Jane; SmithKline Beecham Corporate Intellectual Property, Two New Horizons Court, Brentford, Middlesex TW8 9EP (GB).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: PHENYLUREA AND PHENYLTHIO UREA DERIVATIVES		
(57) Abstract Phenyl urea and phenyl thiourea derivatives and their use as pharmaceuticals.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

PHENYLUREA AND PHENYLTHIO UREA DERIVATIVES

This invention relates to phenyl urea and phenyl thiourea derivatives and their use as pharmaceuticals.

- 5 Many medically significant biological processes are mediated by proteins participating in signal transduction pathways that involve G-proteins and/or second messengers.

Polypeptides and polynucleotides encoding the human 7-transmembrane G-protein coupled neuropeptide receptor, orexin-1 (HFGAN72), have been identified
10 and are disclosed in EP-A-875565, EP-A-875566 and WO 96/34877. Polypeptides and polynucleotides encoding a second human orexin receptor, orexin-2 (HFGANP), have been identified and are disclosed in EP-A-893498.

Polypeptides and polynucleotides encoding polypeptides which are ligands for the orexin-1 receptor, e.g. orexin-A (Lig72A) are disclosed in EP-A-849361.

- 15 Orexin receptors are found in the mammalian host and may be responsible for many biological functions such as pathologies including, but not limited to, depression; anxiety; addictions; obsessive compulsive disorder; affective neurosis/disorder; depressive neurosis/disorder; anxiety neurosis; dysthymic disorder; behaviour disorder; mood disorder; sexual dysfunction; psychosexual
20 dysfunction; sex disorder; sexual disorder; schizophrenia; manic depression; delerium; dementia; severe mental retardation and dyskinesias such as Huntington's disease and Gilles de la Tourette's syndrome; feeding disorders such as anorexia, bulimia, cachexia and obesity; diabetes; appetite/taste disorders; vomiting/nausea; asthma; cancer; Parkinson's disease; Cushing's syndrome / disease; basophil
25 adenoma; prolactinoma; hyperprolactinemia; hypopituitarism; hypophysis tumor / adenoma; hypothalamic diseases; Froehlich's syndrome; adrenohypophysis disease: hypophysis disease; hypophysis tumor / adenoma; pituitary growth hormone; adrenohypophysis hypofunction; adrenohypophysis hyperfunction; hypothalamic hypogonadism; Kallman's syndrome (anosmia, hyposmia); functional or
30 psychogenic amenorrhea; hypopituitarism; hypothalamic hypothyroidism; hypothalamic-adrenal dysfunction; idiopathic hyperprolactinemia; hypothalamic disorders of growth hormone deficiency; idiopathic growth hormone deficiency; dwarfism; gigantism; acromegaly; disturbed biological and circadian rhythms; and sleep disturbances associated with diseases such as neurological disorders.
35 neuropathic pain and restless leg syndrome; heart and lung diseases; acute and congestive heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; ischaemic or haemorrhagic stroke;

subarachnoid haemorrhage; ulcers; allergies; benign prostatic hypertrophy; chronic renal failure; renal disease; impaired glucose tolerance; migraine; hyperalgesia; pain; enhanced or exaggerated sensitivity to pain such as hyperalgesia, causalgia and allodynia; acute pain; burn pain; atypical facial pain; neuropathic pain; back pain; 5 complex regional pain syndromes I and II; arthritic pain; sports injury pain; pain related to infection e.g. HIV, post-polio syndrome and post-herpetic neuralgia; phantom limb pain; labour pain; cancer pain; post-chemotherapy pain; post-stroke pain; post-operative pain; neuralgia; conditions associated with visceral pain such as irritable bowel syndrome, migraine and angina; urinary bladder incontinence e.g. 10 urge incontinence; tolerance to narcotics or withdrawal from narcotics; sleep disorders; sleep apnea; narcolepsy; insomnia; parasomnia; jet-lag syndrome; and neurodegenerative disorders including nosological entities such as disinhibition-dementia-parkinsonism-amyotrophy complex; pallido-ponto-nigral degeneration, epilepsy and seizure disorders.


15 Experiments have shown that central administration of orexin-A stimulates food intake in freely-feeding rats during a 4 hour time period. This increase is approximately four-fold over control rats receiving vehicle. These data suggest that orexin-A may be an endogenous regulator of appetite. Therefore, antagonists of orexin receptors may be useful in the treatment of obesity and diabetes, see *Cell*, 1998, 92, 20 573-585.

Rat sleep/EEG studies have also shown that central administration of orexin-A causes a dose-related increase in arousal, largely at the expense of a reduction in paradoxical sleep and slow wave sleep 2, when administered at the onset of the normal sleep period. Therefore, antagonists of orexin receptors may be useful in the 25 treatment of sleep disorders including insomnia.

The present invention provides phenyl urea and phenyl thiourea derivatives which are non-peptide antagonists of human orexin receptors, in particular orexin-1 receptors. In particular, these compounds are of potential use in the treatment of obesity, including obesity observed in Type 2 (non-insulin-dependent) diabetes 30 patients, and/or sleep disorders.

International Patent Application PCT/GB98/02437 (published after the priority date of the present application) discloses various phenyl urea derivatives as orexin receptor antagonists.

35 According to the invention there is provided a compound of formula (I):



(I)

in which :

one of X and Y is N and the other is CH;

5 Z represents oxygen or sulphur;

R¹ represents (C₁₋₆)alkyl, (C₂₋₆)alkenyl or (C₁₋₆)alkoxy, any of which may be optionally substituted; halogen, R⁷CO- or NR⁸R⁹CO-;

10 R², R³, R⁴, R⁵ and R⁶ independently represent (C₁₋₆)alkyl, (C₂₋₆)alkenyl, (C₁₋₆)alkoxy or (C₁₋₆)alkylthio, any of which may be optionally substituted; hydrogen, halogen, nitro, cyano, aryloxy, aryl(C₁₋₆)alkyloxy, aryl(C₁₋₆)alkyl, R⁷CO-, R⁷SO₂NH-, R⁷CON(R¹⁰)-, NR⁸R⁹-, NR⁸R⁹CO-, -COOR⁸, heterocyclyl or heterocyclyl(C₁₋₆)alkyl; or an adjacent pair of R², R³, R⁴, R⁵ and R⁶ together with the carbon atoms to which they are attached form an optionally substituted carbocyclic or heterocyclic ring;

R⁷ is (C₁₋₆)alkyl or aryl;

15 R⁸ and R⁹ independently represent hydrogen, (C₁₋₆)alkyl, aryl or aryl(C₁₋₆)alkyl;

R¹⁰ is hydrogen or (C₁₋₆)alkyl; and

n is 0, 1, 2, or 3;

or a pharmaceutically acceptable salt thereof.

20 When a halogen atom is present in the compound of formula (I) it may be fluorine, chlorine, bromine or iodine.

Z preferably represents oxygen.

n is preferably 0 or 1.

X is preferably N and Y is CH.

25 When n is 1, the group R¹ is preferably in the 6- or 8-position, particularly the 8-position.

R¹ is preferably halogen e.g. fluoro, or (C₁₋₆)alkoxy e.g. methoxy. R¹ is most preferably fluoro.

When any of R¹ to R⁶ comprise a (C₁₋₆)alkyl group, whether alone or forming part of a larger group. e.g. alkoxy or alkylthio, the alkyl group may be straight chain.

branched or cyclic, it preferably contains 1 to 4 carbon atoms and is most preferably methyl or ethyl.

When any of R¹ to R⁶ comprise a (C₂₋₆)alkenyl group, whether alone or forming part of a larger group, the alkenyl group may be straight chain, branched or cyclic, it preferably contains 2 to 4 carbon atoms and is most preferably allyl.

Suitable optional substituents for (C₁₋₆)alkyl, (C₂₋₆)alkenyl, (C₁₋₆)alkoxy and (C₁₋₆)alkylthio groups include one or more substituents selected from halogen e.g. fluoro, (C₁₋₆)alkoxy e.g. methoxy, hydroxy, carboxy and (C₁₋₆)alkyl esters thereof, amino, mono- or di-(C₁₋₆)alkylamino and cyano.

When used herein the term "aryl", whether alone or forming part of a larger group, includes optionally substituted aryl groups such as phenyl and naphthyl, preferably phenyl. The aryl group may have up to 5, preferably 1, 2 or 3 optional substituents. Examples of suitable substituents include halogen, (C₁₋₄)alkyl e.g. methyl, (C₁₋₄)haloalkyl e.g. trifluoromethyl, (C₁₋₄)alkoxy e.g. methoxy, (C₁₋₄)alkoxy(C₁₋₄)alkyl e.g. methoxymethyl, hydroxy, carboxy and (C₁₋₆)alkyl esters thereof, amino, nitro, arylsulphonyl e.g. p-toluenesulphonyl, and (C₁₋₄)alkylsulphonyl e.g. methanesulphonyl.

When any of R² to R⁶ represent heterocyclyl or heterocyclyl(C₁₋₆)alkyl the heterocyclyl group is preferably a 5- to 10-membered monocyclic or bicyclic ring, which may be saturated or unsaturated, for example containing 1, 2 or 3 heteroatoms selected from oxygen, nitrogen and sulphur; for example pyrrolidine, oxazole, morpholine, pyrimidine or phthalimide. A ring containing one or two nitrogen atoms is preferred. The heterocyclyl group may have up to 5, preferably 1, 2 or 3 optional substituents. Examples of suitable substituents include halogen, (C₁₋₄)alkyl e.g. methyl, (C₁₋₄)haloalkyl e.g. trifluoromethyl, (C₁₋₄)alkoxy e.g. methoxy, (C₁₋₄)alkoxy(C₁₋₄)alkyl e.g. methoxymethyl, hydroxy, carboxy and (C₁₋₆)alkyl esters thereof, amino, nitro, arylsulphonyl e.g. p-toluenesulphonyl, and (C₁₋₄)alkylsulphonyl e.g. methanesulphonyl.

When an adjacent pair of R² to R⁶ together with the carbon atoms to which they are attached form a carbocyclic or heterocyclic ring this is preferably a 5- to 7-membered ring, which may be aromatic or non-aromatic. Heterocyclic rings preferably contain 1, 2 or 3 heteroatoms selected from oxygen, nitrogen and sulphur; for example oxazole, imidazole, thiophene, pyran, dioxan, pyrrole or pyrrolidine. A ring containing one nitrogen atom and one oxygen atom is preferred. It is particularly preferred for the nitrogen to be attached directly to the R¹ position. A carbocyclic or heterocyclic ring formed by an adjacent pair of R² to R⁶ together with the carbon atoms to which they are attached may be optionally substituted on carbon or nitrogen by one


or more substituents, e.g. up to 3 substituents. Examples of suitable substituents include =O, (C₁₋₄)alkyl e.g. methyl, aryl(C₁₋₄)alkyl e.g. benzyl or 3-phenylpropyl, aryl e.g. phenyl, (C₁₋₄)alkoxy e.g. methoxy, (C₁₋₄)alkoxy(C₁₋₄)alkyl e.g. methoxymethyl, hydroxy, hydroxy(C₁₋₄)alkyl e.g. hydroxyethyl, R^aCO₂-, R^aCO₂(C₁₋₄)alkyl e.g.

- 5 carboethoxypropyl, cyano, cyano(C₁₋₄)alkyl e.g. 3-cyanopropyl, R^aR^bN and R^aR^bN(C₁₋₄)alkyl; in which R^a and R^b are independently selected from hydrogen and (C₁₋₄)alkyl.

- A preferred group of compounds are those in which R² to R⁶ independently represent hydrogen, halogen, (C₁₋₆)alkoxy e.g. methoxy, (C₁₋₆)alkylthio e.g. methylthio, or NR⁸R⁹ wherein R⁸ and R⁹ preferably represent (C₁₋₆)alkyl e.g. dimethylamino, and at
10 least one of R² to R⁶ is other than hydrogen; or an adjacent pair of R² to R⁶ together with the carbon atoms to which they are attached form an optionally substituted 5- to 7-membered heterocyclic ring, e.g. a 6- or 7-membered non-aromatic heterocyclic ring or a 5- or 6-membered aromatic heterocyclic ring.

- Further preferred groups of compounds are those in which R², R⁵ and R⁶
15 represent hydrogen, or R², R⁴ and R⁶ represent hydrogen. Another preferred group of compounds are those in which either R³ and R⁴, or R³ and R⁵ are other than hydrogen.

A group of compounds according to the invention which may be mentioned are the compounds of formula (Ia):



20

(Ia)

in which :

Z represents oxygen or sulphur;

R³ and R⁴ independently represent hydrogen, halogen, nitro, cyano, (C₁₋₆)alkyl, (C₁₋₆)alkoxy, aryloxy, CF₃O, (C₁₋₆)alkylthio, R⁷CO-, R⁷SO₂NH-, R⁷CON(R¹⁰)-, NR⁸R⁹,
25 NR⁸R⁹CO-, or heterocyclyl;

or R³ and R⁴ together with the carbon atoms to which they are attached form an optionally substituted carbocyclic or heterocyclic ring;

R⁷ is (C₁₋₆)alkyl or aryl;

R⁸ and R⁹ independently represent hydrogen, (C₁₋₆)alkyl, aryl or (C₁₋₆)alkylaryl;

30 and


R^{10} is hydrogen or (C_{1-6}) alkyl;
or a pharmaceutically acceptable salt thereof.

Particular compounds according to the invention include those mentioned in the examples and their pharmaceutically acceptable salts.

5 It will be appreciated that for use in medicine the salts of the compounds of formula (I) should be pharmaceutically acceptable. Suitable pharmaceutically acceptable salts will be apparent to those skilled in the art and include acid addition salts formed with inorganic acids e.g. hydrochloric, hydrobromic, sulphuric, nitric or phosphoric acid; and organic acids e.g. succinic, maleic, acetic, fumaric, citric,
10 tartaric, benzoic, p-toluenesulphonic, methanesulphonic or naphthalenesulphonic acid. Other salts e.g. oxalates, may be used, for example in the isolation of compounds of formula (I) and are included within the scope of this invention. Also included within the scope of the invention are solvates and hydrates of compounds of formula (I).

15 The invention extends to all isomeric forms including stereoisomers and geometric isomers of the compounds of formula (I) including enantiomers and mixtures thereof e.g. racemates. The different isomeric forms may be separated or resolved by conventional methods, or any given isomer may be obtained by conventional synthetic methods or by stereospecific or asymmetric syntheses.


20 According to a further feature of the invention there is provided a process for the preparation of compounds of formula (I) and salts thereof which comprises coupling a compound of formula (II):



(II)

25

with a compound of formula (III):



(III)

wherein A and B are appropriate functional groups to form the -NHCONH- or -NHCSNH- moiety when coupled; n, X and Y are as defined in formula (I); and R^{1'} to R^{6'} are R¹ to R⁶ as defined in formula (I) or groups convertible thereto; and thereafter optionally and as necessary and in any appropriate order, converting any

- 5 R^{1'} to R^{6'} when other than R¹ to R⁶ respectively to R¹ to R⁶, and/or forming a pharmaceutically acceptable salt.

Suitable examples of groups A and B are:

- (i) A and B are -NH₂
 - (ii) one of A and B is -CON₃ and the other is -NH₂
 - 10 (iii) one of A and B is -CO₂H and the other is -NH₂
 - (iv) one of A and B is -N=C=O and the other is -NH₂
 - (v) one of A and B is -N=C=S and the other is -NH₂
 - (vi) one of A and B is -NHCOL and the other is -NH₂
 - (vii) one of A and B is halogen and the other is -NHCONH₂.
- 15 Wherein L is a leaving group such as chloro, bromo, imidazole, or phenoxy or phenylthio optionally substituted for example with halogen, e.g. chlorine.

When A and B are both -NH₂, the reaction is generally effected in the presence of a urea coupling agent such as carbonyldiimidazole.

- 20 When one of A and B is -CO₂H and the other is -NH₂ the reaction is generally effected in the presence of an agent such as diphenylphosphoryl azide and in the presence of a base such as triethylamine.

- When one of A and B is -N=C=O or -N=C=S and the other is -NH₂, the reaction is suitably carried out in an inert solvent e.g. dimethylformamide or dichloromethane and/or toluene at ambient or elevated temperature, preferably
- 25 ambient.

When one of A and B is -CON₃ or -CO₂H and the other is -NH₂ the reaction is suitably carried out in an inert solvent e.g. toluene or dimethylformamide at elevated temperature.

- 30 When one of A and B is -NHCOL and the other is -NH₂ the reaction is suitably carried out in an inert solvent e.g. dichloromethane, at ambient temperature, optionally in the presence of a base e.g. triethylamine; or in dimethylformamide at ambient or elevated temperature.

- When one of A and B is halogen and the other is -NHCONH₂, the reaction is suitably carried out in an inert solvent e.g. toluene, at elevated temperature.
- 35 optionally in the presence of base.

Suitable examples of compounds having groups R^{1'} to R^{6'} which are convertible to R¹ to R⁶ respectively include compounds where one or more of R² to

R^6 are OH or NH_2 , and compounds where an adjacent pair of R^7 to R^6 together with the carbon atoms to which they are attached represent a fused pyrrole ring which is unsubstituted on nitrogen, in this case treatment with a base e.g. sodium hydride, and reaction with an electrophile e.g. methyl iodide, benzyl chloride or benzenesulfonyl chloride, affords the corresponding substituent on the pyrrole nitrogen.

Compounds of formulae (II) and (III) where A or B is $-NH_2$, $-N=C=S$ or halogen are known compounds or can be prepared analogously to known compounds.

Compounds of formulae (II) and (III) where A or B is $-N=C=O$ may be prepared by treating a compound of formula (II) in which:

- (i) A or B is amino, with phosgene or a phosgene equivalent, in the presence of excess base or an inert solvent;
- (ii) A or B is acylazide (i.e. $-CON_3$), via the nitrene, by thermal rearrangement using conventional conditions (ref. L.S. Trifonov *et al*, *Helv. Chim. Acta*, 1987, 70, 262); or
- (iii) A or B is $-CONH_2$, via the nitrene intermediate using conventional conditions.

Compounds of formulae (II) and (III) where A or B is $-NHCOL$ may be prepared by reacting a compound of formula (II) or (III) in which A or B is $-NH_2$ with phosgene or a phosgene equivalent, in an inert solvent, at low temperature, if necessary in the presence of a base e.g. triethylamine.

Examples of phosgene equivalents include triphosgene, carbonyldiimidazole, phenyl chloroformate and phenyl chlorothioformate.


Compounds of formulae (II) and (III) where A or B is $-NHCONH_2$ can be prepared from compounds of formulae (II) and (III) where A or B is $-NH_2$ by reaction with an isocyanate under conventional conditions.

The compounds of formula (I) may be prepared singly or as compound libraries comprising at least 2, e.g. 5 to 1000, preferably 10 to 100 compounds of formula (I). Compound libraries may be prepared by a combinatorial 'split and mix' approach or by multiple parallel synthesis using either solution phase or solid phase chemistry, by procedures known to those skilled in the art.

Thus according to a further aspect of the invention there is provided a compound library comprising at least 2 compounds of formula (I), or pharmaceutically acceptable salts thereof.

Novel intermediates of formulae (II) and (III) are also part of this invention.

According to a further aspect of the invention there is provided a compound of formula (II):



(II)

wherein A is -CON₃, -NH₂, -CO₂H, -N=C=O, -N=C=S, -NHCOL, -NHCONH₂ or halogen; L is a leaving group; n, X and Y are as defined in formula (I); and R¹ is R¹ as defined in formula (I) or a group convertible thereto.

Pharmaceutically acceptable salts may be prepared conventionally by reaction with the appropriate acid or acid derivative.

The compounds of formula (I) and their pharmaceutically acceptable salts are useful for the treatment of diseases or disorders where an antagonist of a human orexin receptor is required such as obesity and diabetes; prolactinoma; hypoprolactinemia; hypothalamic disorders of growth hormone deficiency; idiopathic growth hormone deficiency; Cushing's syndrome/disease; hypothalamic-adrenal dysfunction; dwarfism; sleep disorders; sleep apnea; narcolepsy; insomnia; parasomnia; jet-lag syndrome; sleep disturbances associated with diseases such as neurological disorders, neuropathic pain and restless leg syndrome; heart and lung diseases; depression; anxiety; addictions; obsessive compulsive disorder; affective neurosis/disorder; depressive neurosis/disorder; anxiety neurosis; dysthymic disorder; behaviour disorder; mood disorder; sexual dysfunction; psychosexual dysfunction; sex disorder; sexual disorder; schizophrenia; manic depression; delirium; dementia; bulimia; and hypopituitarism.

The compounds of formula (I) and their pharmaceutically acceptable salts are particularly useful for the treatment of obesity, including obesity associated with Type 2 diabetes, and sleep disorders.

Other diseases or disorders which may be treated in accordance with the invention include disturbed biological and circadian rhythms; adrenohypophysis disease; hypophysis disease; hypophysis tumor / adenoma; adrenohypophysis hypofunction; functional or psychogenic amenorrhea; adrenohypophysis hyperfunction; migraine; hyperalgesia; pain; enhanced or exaggerated sensitivity to pain such as hyperalgesia, causalgia and allodynia; acute pain; burn pain; atypical facial pain; neuropathic pain; back pain; complex regional pain syndromes I and II; arthritic pain; sports injury pain; pain related to infection e.g. HIV, post-polio syndrome and post-herpetic neuralgia; phantom limb pain; labour pain; cancer pain; post-chemotherapy pain; post-stroke pain; post-operative pain; neuralgia; and tolerance to narcotics or withdrawal from narcotics.

The invention also provides a method of treating or preventing diseases or disorders where an antagonist of a human orexin receptor is required, which comprises administering to a subject in need thereof an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof.

- 5 The invention also provides a compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in the treatment or prophylaxis of diseases or disorders where an antagonist of a human orexin receptor is required.

- 10 The invention also provides the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment or prophylaxis of diseases or disorders where an antagonist of a human orexin receptor is required.

- 15 For use in therapy the compounds of the invention are usually administered as a pharmaceutical composition. The invention also provides a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

The compounds of formula (I) and their pharmaceutically acceptable salts may be administered by any convenient method, e.g. by oral, parenteral, buccal, sublingual, nasal, rectal or transdermal administration, and the pharmaceutical compositions adapted accordingly.

- 20 The compounds of formula (I) and their pharmaceutically acceptable salts which are active when given orally can be formulated as liquids or solids, e.g. as syrups, suspensions, emulsions, tablets, capsules or lozenges.

- 25 A liquid formulation will generally consist of a suspension or solution of the active ingredient in a suitable liquid carrier(s) e.g. an aqueous solvent such as water, ethanol or glycerine, or a non-aqueous solvent, such as polyethylene glycol or an oil. The formulation may also contain a suspending agent, preservative, flavouring and/or colouring agent.

- 30 A composition in the form of a tablet can be prepared using any suitable pharmaceutical carrier(s) routinely used for preparing solid formulations, such as magnesium stearate, starch, lactose, sucrose and cellulose.

- 35 A composition in the form of a capsule can be prepared using routine encapsulation procedures, e.g. pellets containing the active ingredient can be prepared using standard carriers and then filled into a hard gelatin capsule; alternatively a dispersion or suspension can be prepared using any suitable pharmaceutical carrier(s), e.g. aqueous gums, celluloses, silicates or oils and the dispersion or suspension then filled into a soft gelatin capsule.

Typical parenteral compositions consist of a solution or suspension of the active ingredient in a sterile aqueous carrier or parenterally acceptable oil, e.g. polyethylene glycol, polyvinyl pyrrolidone, lecithin, arachis oil or sesame oil. Alternatively, the solution can be lyophilised and then reconstituted with a suitable solvent just prior to administration.

Compositions for nasal administration may conveniently be formulated as aerosols, drops, gels and powders. Aerosol formulations typically comprise a solution or fine suspension of the active ingredient in a pharmaceutically acceptable aqueous or non-aqueous solvent and are usually presented in single or multidose quantities in sterile form in a sealed container which can take the form of a cartridge or refill for use with an atomising device. Alternatively the sealed container may be a disposable dispensing device such as a single dose nasal inhaler or an aerosol dispenser fitted with a metering valve. Where the dosage form comprises an aerosol dispenser, it will contain a propellant which can be a compressed gas e.g. air, or an organic propellant such as a fluorochlorohydrocarbon or hydrofluorocarbon. Aerosol dosage forms can also take the form of pump-atomisers.

Compositions suitable for buccal or sublingual administration include tablets, lozenges and pastilles where the active ingredient is formulated with a carrier such as sugar and acacia, tragacanth, or gelatin and glycerin.

Compositions for rectal administration are conveniently in the form of suppositories containing a conventional suppository base such as cocoa butter.

Compositions suitable for transdermal administration include ointments, gels and patches.

Preferably the composition is in unit dose form such as a tablet, capsule or ampoule.

The dose of the compound of formula (I), or a pharmaceutically acceptable salt thereof, used in the treatment or prophylaxis of the abovementioned disorders or diseases will vary in the usual way with the particular disorder or disease being treated, the weight of the subject and other similar factors. However, as a general rule, suitable unit doses may be 0.05 to 1000 mg, more suitably 0.05 to 500 mg. Unit doses may be administered more than once a day for example two or three times a day, so that the total daily dosage is in the range of about 0.01 to 100 mg/kg; and such therapy may extend for a number of weeks or months. In the case of pharmaceutically acceptable salts the above figures are calculated as the parent compound of formula (I).

No toxicological effects are indicated/expected when a compound of formula (I) is administered in the above mentioned dosage range.

Human orexin-A has the amino acid sequence:

	pyroGlu	Pro	Leu	Pro	Asp	Cys	Cys	Arg	Gln	Lys	Thr	Cys	Ser	Cys	Arg	Leu
	1		5		10		15									
	Tyr	Glu	Leu	Leu	His	Gly	Ala	Gly	Asn	His	Ala	Ala	Gly	Ile	Leu	Thr
5			20		25		30									
	Leu-NH ₂															

Orexin-A can be employed in screening procedures for compounds which inhibit the ligand's activation of the orexin-1 receptor.

In general, such screening procedures involve providing appropriate cells which express the orexin-1 receptor on their surface. Such cells include cells from mammals, yeast, *Drosophila* or *E. coli*. In particular, a polynucleotide encoding the orexin-1 receptor is used to transfect cells to express the receptor. The expressed receptor is then contacted with a test compound and an orexin-1 receptor ligand to observe inhibition of a functional response. One such screening procedure involves the use of melanophores which are transfected to express the orexin-1 receptor, as described in WO 92/01810.

Another screening procedure involves introducing RNA encoding the orexin-1 receptor into *Xenopus* oocytes to transiently express the receptor. The receptor oocytes are then contacted with a receptor ligand and a test compound, followed by detection of inhibition of a signal in the case of screening for compounds which are thought to inhibit activation of the receptor by the ligand.

Another method involves screening for compounds which inhibit activation of the receptor by determining inhibition of binding of a labelled orexin-1 receptor ligand to cells which have the receptor on their surface. This method involves transfecting a eukaryotic cell with DNA encoding the orexin-1 receptor such that the cell expresses the receptor on its surface and contacting the cell or cell membrane preparation with a compound in the presence of a labelled form of an orexin-1 receptor ligand. The ligand may contain a radioactive label. The amount of labelled ligand bound to the receptors is measured, e.g. by measuring radioactivity.

Yet another screening technique involves the use of FLIPR equipment for high throughput screening of test compounds that inhibit mobilisation of intracellular calcium ions, or other ions, by affecting the interaction of an orexin-1 receptor ligand with the orexin-1 receptor.

All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth.

The following Examples illustrate the preparation of pharmacologically active compounds of the invention. The Descriptions D1-D10 illustrate the preparation of intermediates to compounds of the invention.

- 5 In the Examples ¹H NMR's were measured at 250MHz in d₆-DMSO unless otherwise stated. All hydrochloride salts unless otherwise stated were prepared by dissolving/suspending the free-base in methanol and treating with an excess of ethereal HCl (1M).

Description 1

10 4-Chloro-[1,5]naphthyridine

- 4-Hydroxy-[1,5]naphthyridine-3-carboxylic acid (14.00 g, Joe T. Adams *et al.*, *J.Amer.Chem.Soc.*, 1946, 68, 1317) in quinoline (150 ml) was heated at reflux under argon for 1h. The reaction mixture was cooled to room temperature then poured onto diethyl ether (500 ml). The precipitated crude 4-hydroxy-
- 15 [1,5]naphthyridine was collected by filtration, washed with diethyl ether (4x300 ml) and dried *in vacuo*. A sample of the solid (5.00 g) was heated in phosphorus oxychloride (100 ml) at 115°C for 1h. The reaction mixture was cooled to room temperature and the resulting black oil treated with crushed ice with ice-salt bath cooling. The mixture was basified with .880 ammonia, then filtered through
- 20 kieselguhr, washing with ethyl acetate. The organic phase of the filtrate was separated and the aqueous residues washed with ethyl acetate. The combined organics were washed with saturated aqueous sodium chloride and dried (Na₂SO₄). Removal of the solvent under reduced pressure afforded the title compound as a waxy yellow solid (1.90 g).
- 25 ¹H NMR (CDCl₃) δ: 7.74 (2H, m), 8.46 (1H, dd, J=2+9Hz), 8.87 (1H, d, J=5Hz), 9.11 (1H, dd, J=2+4Hz).
- m/z (API⁺): 165, 167 (MH⁺).

Description 2

30 4-Amino-[1,5]naphthyridine

- A solution of D1 (1.90 g) in pyridine (80 ml) was treated with n-propylamine hydrochloride (5.59 g) and the mixture heated at reflux under argon for 5h. The reaction mixture was cooled and the pyridine removed under reduced pressure. The residue was treated with aqueous sodium hydroxide (10%) and the resulting solution
- 35 extracted with diethyl ether. The combined organics were dried (Na₂SO₄) and the solvent removed under reduced pressure to give a sticky solid. Trituration with pentane afforded the title compound as a dark yellow solid (1.39 g).

¹H NMR (CDCl₃) δ: 5.54 (2H, bs), 6.74 (1H, d, J=5Hz), 7.58 (1H, dd, J=4+8Hz), 8.25 (1H, dd, J=2+8Hz), 8.53 (1H, d, J=5Hz), 8.75 (1H, dd, J=2+4Hz).
m/z (API⁺): 146 (MH⁺).

5 Description 3

4-Hydroxy-[1,6]naphthyridine-3-carboxylic acid ethyl ester

4-Aminopyridine (15.84 g) and diethyl ethoxymethylenemalonate (34.3 ml) were heated at 110°C then allowed to stand for 16h at room temperature. The resulting solid was collected by filtration, washed with diethyl ether then pentane and dried *in vacuo*. A sample of the resulting enamine (10.0 g) was added portionwise to refluxing Dowtherm A (400 ml). After heating for a further 0.25h the reaction mixture was cooled then diluted with pentane (400 ml). The precipitated solid was collected by filtration and washed with diethyl ether to afford the title compound as a beige solid (3.84 g).

10 ¹H NMR δ: 1.29 (3H, t, J=7Hz), 4.23 (2H, q, J=7Hz), 7.53 (1H, d, J=6Hz), 8.64 (1H, s), 8.68 (1H, d, J=6Hz), 9.25 (1H, s), 12.5 (1H, bs).
m/z (API⁺): 219 (MH⁺).

Description 4

20 4-Hydroxy-[1,6]naphthyridine-3-carboxylic acid

D3 (7.50 g) in 10% aqueous sodium hydroxide (115 ml) was heated at reflux for 1.5h. The reaction mixture was cooled then acidified with glacial acetic acid. The precipitated solid was collected by filtration and washed with water. Drying *in vacuo* afforded the title compound as a beige solid (6.41 g).

25 ¹H NMR δ: 7.72 (1H, dd, J=1+6Hz), 8.84 (1H, d, J=6 Hz), 9.03 (1H, s), 9.46 (1H, s), 13.55 (1H, bs), 14.70 (1H, bs).
m/z (API⁺): 191 (MH⁺).

Description 5

30 4-Chloro-[1,6]naphthyridine

D4 (6.3 g) was decarboxylated and a sample (2.00 g) converted to the title compound (0.76 g) by treatment with phosphorus oxychloride as in Description 1.

¹H NMR (CDCl₃) δ: 7.60 (1H, d, J=5Hz), 7.95 (1H, d, J=6Hz), 8.86 (1H, d, J=6Hz), 8.97 (1H, d, J=5Hz), 9.68 (1H, s).
35 m/z (API⁺): 165, 167 (MH⁺).

Description 6

4-Amino-[1,6]naphthyridine

A solution of D5 (0.700 g) in pyridine (20 ml) was treated with n-propylamine hydrochloride (2.064 g) and the mixture heated at reflux for 16h. The reaction mixture was cooled and partitioned between water and ethyl acetate. The aqueous phase was washed with ethyl acetate, the combined organics dried (Na₂SO₄) and the solvent removed under reduced pressure. Trituration with pentane afforded the title compound as a brown solid (0.100 g).

¹H NMR (CDCl₃) δ: 5.12 (2H, bs), 6.66 (1H, d, J=5Hz), 7.78 (1H, d, J=6Hz), 6.66 (2H, m), 9.24 (1H, s).

m/z (API⁺): 146 (MH⁺).

In addition, a sample of the hydrochloride salt (0.200 g) of the title compound was isolated from the aqueous phase obtained on work-up.

¹H NMR δ: 6.91 (1H, d, J=7Hz), 7.83 (1H, d, J=6Hz), 8.48 (1H, d, J=7Hz), 8.84 (1H, d, J=6Hz), 9.65 (2H, bs), 9.85 (1H, s).

m/z (API⁺): 146 (MH⁺).

Description 74-Hydroxy-6-methoxy-[1,5]naphthyridine-3-carboxylic acid ethyl ester

3-Amino-6-methoxypyridine (12.41 g) and diethyl ethoxymethylene malonate (20.2 ml) in Dowtherm A (400 ml) were heated at reflux, under argon for 1h. The cooled reaction mixture was poured onto pentane (1 litre). The precipitated solid was collected by filtration, washing with pentane. Drying afforded the title compound (24.78 g, crude).

Description 84-Hydroxy-6-methoxy-[1,5]naphthyridine-3-carboxylic acid

D7 (642 mg) was converted to the title compound (542 mg) by treatment with aqueous sodium hydroxide (10%) as in Description 4.

m/z: 221 (MH⁺).

Description 94-Chloro-6-methoxy-[1,5]naphthyridine

D8 (6.82 g) was decarboxylated and a sample (3.87 g) converted to the title compound (3.00 g) by treatment with phosphorus oxychloride as in Description 1.

m/z: 195.197 (MH⁺).

Description 10

4-Amino-6-methoxy-[1,5]naphthyridine

- D6 (2.00 g) was converted to the title compound by treatment with n-propylamine hydrochloride in pyridine as in Description 2. Purification by chromatography on silica gel eluting with 5-10% methanol in dichloromethane afforded the title compound as a yellow solid (1.00 g).
¹H NMR (CDCl₃) δ: 4.05 (3H, s), 5.36 (2H, bs), 6.71 (1H, d, J=5 Hz), 7.08 (1H, d, J=9Hz), 8.10 (1H, d, J=9Hz), 8.40 (1H, d, J=5Hz).
m/z: 176 (MH⁺).

10 Example 11-(4-Dimethylaminophenyl)-3-[1,5]naphthyridin-4-yl urea dihydrochlorideMethod 1

- Sodium hydride (0.024 g, 60% in mineral oil) was added to a solution of D2 (0.073 g) in dimethylformamide (5 ml) under argon. The mixture was stirred for 0.5h then 4-N,N-dimethylaminophenyl isocyanate (0.081 g) added in one portion. The mixture was stirred for 2h at room temperature then warmed to 80°C for 1h. The mixture was cooled to room temperature and added carefully to water (20 ml). The precipitated solid was collected by filtration to give the title compound as the free-base and the hydrochloride salt (0.040 g) was prepared.
¹H NMR δ: 3.06 (6H, s), 7.60 (4H, m), 8.15 (1H, dd, J=4+9Hz), 8.67 (1H, dd, J=1+9Hz), 8.74 (1H, d, J=6Hz), 9.07 (1H, d, J=6Hz), 9.20 (1H, dd, J=1+4Hz), 10.74 (1H, bs), 10.86 (1H, s).
m/z (API⁺): 308 (MH⁺).

25 Method 2

- Sodium hydride (0.096 g, 60% in mineral oil) was added to a solution of D2 (0.292 g) in dimethylformamide (15 ml) under argon. The mixture was stirred for 0.5h then 4-N,N-dimethylaminophenyl isocyanate (0.324 g) added in one portion. The mixture was stirred for 2h at room temperature. The reaction mixture was added carefully to water (20 ml) and extracted with ethyl acetate (3 x 15 ml). The combined organic phases were washed with water (2 x 75 ml), dried (Na₂SO₄) and the solvent removed at reduced pressure. Chromatography on silica gel eluting with 20-100% ethyl acetate in hexane afforded the the title compound as the free-base. The hydrochloride salt (0.306 g) was prepared. This material was identical spectroscopically with the material from Method 1.

Method 3

A mixture of D2 (0.145 g) and 4-N,N-dimethylaminophenyl isocyanate (0.162 g) in dichloromethane (10 ml) under argon was stirred for 16h. 4-Dimethylaminopyridine (0.002 g) was added and stirring continued for 2h. A further portion of the isocyanate (0.100 g) was added and stirring continued for 4h.

5 The solvent was removed at reduced pressure and the residue triturated with methanol. The solid material was removed by filtration and the filtrate evaporated to dryness. Chromatography on silica gel eluting with 20-100% ethyl acetate in hexane afforded the title compound as the free-base. The hydrochloride salt (0.060 g) was prepared. This material was identical spectroscopically with the material from

10 Method 1.

Example 2

1-(4-Methylthiophenyl)-3-[1,5]naphthyridin-4-yl urea hydrochloride

The title compound (0.050 g) was prepared according to the method of

15 Example 1, Method 2 using D2 (0.073 g) and 4-methylthiophenyl isocyanate (0.083 g). The crude reaction mixture was purified by trituration with diethyl ether and the hydrochloride salt was prepared.

¹H NMR δ: 2.49 (3H, s), 7.30 (2H, d, J=9Hz), 7.53 (2H, d, J=9Hz), 8.14 (1H, dd, J=4+9Hz), 8.66 (1H, dd, J=1+9Hz), 8.72 (1H, d, J=7Hz), 9.05 (1H, d, J=7Hz), 9.19

20 (1H, dd, J=1+4Hz), 10.57 (1H, s), 10.81 (1H, s).

m/z (API⁺): 311 (MH⁺).

Example 3

1-(4-Dimethylaminophenyl)-3-[1,5]naphthyridin-4-yl thiourea dihydrochloride

25 The title compound (0.020 g) was prepared according to the method of Example 1, Method 2 from D2 (0.073 g) and 4-N,N-dimethylaminophenyl isothiocyanate (0.089 g). After pouring into water, the precipitated solid was collected by filtration. The solid was dissolved in methanol/dichloromethane, the solution filtered and the filtrate evaporated to dryness. The resulting solid was

30 triturated with diethyl ether to give the title compound as the free-base and the hydrochloride salt was prepared.

¹H NMR δ: 3.04 (6H, s), 7.28 (2H, bs), 7.64 (7.65 (2H, bd), 8.16 (1H, dd, J=4+9Hz), 8.70 (1H, d, J=9Hz), 9.10 (1H, d, J=7Hz), 9.19 (1H, bs), 9.61 (1H, d, J=7Hz), 11.45

(1H, bs), 11.96 (1H, bs).

35 m/z (API⁺): 324 (MH⁺).

Example 4

1-(4-Dimethylaminophenyl)-3-[1,6] naphthyridin-4-yl urea

The title compound (0.100 g) was prepared from D6 (0.073 g) and 4-N,N-dimethylaminophenyl isocyanate (0.081 g) according to the method of Example 1, Method 2. Chromatography on silica gel, eluting with 40-100 % ethyl acetate in pentane afforded the title compound.

¹H NMR δ: 2.87 (6H, s), 6.75 (2H, d, J=9Hz), 7.35 (2H, d, J=9Hz), 7.82 (1H, d, J=6Hz), 8.33 (1H, d, J=5Hz), 8.72 (1H, d, J=6Hz), 8.87 (1H, d, J=5Hz), 8.98 (1H, s), 9.57 (1H, s), 9.64 (1H, s).

m/z (API⁺): 308 (MH⁺), 330 (Na adduct).

Example 51-(1-Methylindol-5-yl)-3-[1,5]naphthyridin-4-yl urea hydrochloride

1-Methyl-5-aminoindole (0.142 g) in dichloromethane (5 ml) was added dropwise to a stirred solution of 1,1'-carbonyldiimidazole (0.157 g) in dichloromethane (5 ml) under argon. The mixture was stirred for 2h at room temperature and solvent removed at reduced pressure. The residue was dissolved in dimethylformamide (3 ml) and added to a solution of D2 (0.142 g), pretreated for 0.5h with sodium hydride (0.096 g, 60% in oil), in dimethylformamide (4 ml). The mixture was stirred for 0.5h at room temperature and at 100°C for 0.5h, cooled to room temperature and poured into water (75 ml). The resultant mixture stood at 0°C overnight then was extracted with ethyl acetate (2x30 ml). The combined organic extracts were washed with water (2x30 ml) then saturated aqueous sodium chloride, dried (Na₂SO₄) and the solvent removed at reduced pressure. The residue was column chromatographed on silica gel, eluting with 20-100% ethyl acetate in hexane, to give the title compound as the free-base (0.095 g). The hydrochloride salt (0.065 g) was prepared.

¹H NMR δ: 3.79 (3H, s), 6.41 (1H, d, J=3Hz), 7.26 (1H, d, J=9Hz), 7.34 (1H, d, J=3Hz), 7.43 (1H, d, J=9Hz), 7.84 (1H, s), 8.15 (1H, dd, J=4+9Hz), 8.67 (1H, d, J=9Hz), 8.76 (1H, d, J=7Hz), 9.05 (1H, d, J=7Hz), 9.20 (1H, d, J=4 Hz), 10.40 (1H, s), 10.85 (1H, s).

m/z (API⁺): 318 (MH⁺).

Example 61-(2-Methylbenzoxazol-6-yl)-3-[1,5] naphthyridin-4-yl urea hydrochloride

A slurry of 2-methyl-6-benzoxazole carboxylic acid (0.953 g) in toluene (100 ml) was treated with triethylamine (0.78 ml) then diphenylphosphoryl azide (1.48 ml). Dimethylformamide (20 ml) was added and the mixture heated at 65°C for

0.75h under argon. The reaction mixture was cooled to room temperature and D2 (0.781 g) added. Heating at 65°C was continued for a further 72h. The cooled reaction mixture was diluted with ethyl acetate and washed with saturated aqueous sodium carbonate. The organic phase was dried (Na₂SO₄) and the solvent removed at reduced pressure to give the free-base of the title compound (crude). The hydrochloride salt was prepared and triturated with cold methanol to give the title compound as a yellow solid (0.920 g).

¹H NMR δ: 2.61 (3H, s), 7.30 (1H, dd, J=2+9Hz), 7.63 (1H, d, J=9Hz), 8.08 (1H, d, J=2Hz), 8.13 (1H, dd, J=4+9Hz), 8.62 (1H, dd, J=1+9Hz), 8.73 (1H, d, J=6Hz), 9.09 (1H, d, J=6Hz), 9.19 (1H, dd, J=1+4Hz), 10.71 (1H, s), 10.79 (1H, s).

m/z (API⁺): 320 (MH⁺).

Example 7

1-(4-Methyl-3,4-dihydro-2H-benzo[1,4]oxazin-7-yl)-3-[1,5]naphthyridin-4-yl urea dihydrochloride

A solution of 1,1-carbonyldiimidazole (0.099 g) in dichloromethane (5 ml) was treated dropwise with a solution of 4-methyl-3,4-dihydro-2H-benzo[1,4]oxazin-7-ylamine (0.100 g) in dichloromethane (5 ml) under argon. After stirring for 2h at room temperature the solvent was removed at reduced pressure and the residue dissolved in dimethylformamide (5 ml). This was added to a stirring mixture of D2 (0.088 g) and sodium hydride (0.0610 g, 60% dispersion in mineral oil) in dimethylformamide (5 ml). The mixture was stirred at room temperature for 0.5 h then partitioned between water and ethyl acetate. The organic phase was dried (Na₂SO₄) and the solvent removed at reduced pressure. Chromatography on silica gel, eluting with 20-60% ethyl acetate in pentane, afforded impure product which was chromatographed a second time (conditions as above) to give the free-base of the title compound. The hydrochloride salt was prepared and crystallised from methanol to give the title compound (0.011 g).

¹H NMR δ: 2.83 (3H, s), 3.23 (2H, bt), 4.28 (2H, bt), 5.69 (bs), 6.75 (1H, d, J=9Hz), 6.94 (1H, dd, J=2+9Hz), 7.02 (1H, d, J=2Hz), 8.16 (1H, dd, J=4+9Hz), 8.69 (1H, dd, J=1+9Hz), 8.74 (1H, d, J=6Hz), 9.05 (1H, d, J=6Hz), 9.20 (1H, dd, J=1+4Hz), 10.32 (1H, s), 10.83 (1H, s).

m/z (API⁺): 336 (MH⁺).

Example 8

1-(2-Methylbenzoxazol-6-yl)-3-[1,6]naphthyridin-4-yl urea hydrochloride

- A slurry of 2-methyl-6-benzoxazole carboxylic acid (0.089 g) in toluene (10 ml) was treated with triethylamine (0.071 ml) then diphenylphosphoryl azide (0.139 ml) and the mixture heated at 65°C for 0.75h under argon. The reaction mixture was cooled to room temperature and D6 (0.091 g) in dimethylformamide (2 ml) and triethylamine (0.071 ml) added. Heating at 65°C was continued for a further 16h. The mixture was cooled to room temperature and the solvent removed at reduced pressure. Chromatography on silica gel, eluting with 20-100% ethyl acetate in pentane then 1-5% methanol in ethyl acetate afforded the title compound as the free-base. The hydrochloride salt (0.040 g) was prepared.
- ¹H NMR δ: 2.61 (3H, s), 7.32 (1H, dd, J=2+8Hz), 7.65 (1H, d, J=8Hz), 8.06 (1H, d, J=2Hz), 8.10 (1H, d, J=6Hz), 8.77 (1H, d, J=7Hz), 8.99 (1H, d, J=6Hz), 9.13 (1H, d, J=7Hz), 10.54 (1H, s), 11.42 (1H, s), 11.74 (1H, bs).
- m/z (API⁺): 320 (MH⁺).

Example 9

1-(4-Dimethylaminophenyl)-3-(6-methoxy-[1,5]naphthyridin-4-yl) urea

- A mixture of D10 (50 mg), 4-dimethylaminopyridine (2 mg) and 4-dimethylaminophenyl isocyanate (47 mg) in dichloromethane (8 ml) was stirred at room temperature, under argon for 16h. The solvent was removed under reduced pressure. Chromatography on silica gel eluting with 1-3% methanol in dichloromethane afforded the title compound as a white solid (8 mg).
- ¹H NMR (CDCl₃) δ: 2.99 (6H, s), 3.50 (3H, s), 6.40 (1H, bs), 6.75 (1H, d, J=9Hz), 7.02 (1H, d, J=9Hz), 7.27 (3H, m), 8.12 (1H, d, J=9Hz), 8.41 (1H, d, J=5Hz), 8.64 (1H, d, J=5Hz), 8.90 (1H, bs).
- m/z: 337 (MH⁺).

Determination of Orexin-1 Receptor Antagonist Activity

The orexin-1 receptor antagonist activity of the compounds of formula (I) was determined in accordance with the following experimental method.

Experimental Method

- HEK293 cells expressing the human orexin-1 receptor were grown in cell medium (MEM medium with Earl's salts) containing 2 mM L-Glutamine, 0.4 mg/mL G418 Sulphate from GIBCO BRL and 10% heat inactivated fetal calf serum from Gibco BRL. The cells were seeded at 20,000 cells/100 µl/well into 96-well black clear bottom sterile plates from Costar which had been pre-coated with 10 µg/well of poly-L-lysine from SIGMA. The seeded plates were incubated overnight at 37°C in 5% CO₂.

Agonists were prepared as 1 mM stocks in water:DMSO (1:1). EC₅₀ values (the concentration required to produce 50% maximal response) were estimated using 11x half log unit dilutions (Biomek 2000, Beckman) in Tyrode's buffer containing probenecid (10 mM HEPES with 145mM NaCl, 10mM glucose, 2.5 mM KCl, 1.5 mM CaCl₂, 1.2 mM MgCl₂ and 2.5mM probenecid; pH7.4). Antagonists were prepared as 10 mM stocks in DMSO (100%). Antagonist IC₅₀ values (the concentration of compound needed to inhibit 50% of the agonist response) were determined against 3.0 nM human orexin-A using 11x half log unit dilutions in Tyrode's buffer containing 10% DMSO and probenecid.

On the day of assay 50 µl of cell medium containing probenecid (Sigma) and Fluo3AM (Texas Fluorescence Laboratories) was added (Quadra, Tomtec) to each well to give final concentrations of 2.5 mM and 4 µM, respectively. The 96-well plates were incubated for 90 min at 37°C in 5% CO₂. The loading solution containing dye was then aspirated and cells were washed with 4x150 µl Tyrode's buffer containing probenecid and 0.1% gelatin (Denley Cell Wash). The volume of buffer left in each well was 125 µl. Antagonist or buffer (25 µl) was added (Quadra) the cell plates gently shaken and incubated at 37°C in 5% CO₂ for 30 min. Cell plates were then transferred to the Fluorescent Imaging Plate Reader (FLIPR, Molecular Devices) instrument and maintained at 37°C in humidified air. Prior to drug addition a single image of the cell plate was taken (signal test), to evaluate dye loading consistency. The run protocol used 60 images taken at 1 second intervals followed by a further 24 images at 5 second intervals. Agonists were added (by the FLIPR) after 20 sec (during continuous reading). From each well, peak fluorescence was determined over the whole assay period and the mean of readings 1-19 inclusive was subtracted from this figure. The peak increase in fluorescence was plotted against compound concentration and iteratively curve fitted using a four parameter logistic fit (as described by Bowen and Jerman, *TIPS*, 1995, 16, 413-417) to generate a concentration effect value. Antagonist Kb values were calculated using the equation:


$$K_b = IC_{50} / (1 + (3/EC_{50}))$$

where EC₅₀ was the potency of human orexin-A determined in the assay (in nM terms) and IC₅₀ is expressed in molar terms.

As an illustration of the activity of the compounds of formula (I), the compounds of Examples 1 and 2 each had a pK_b > 7 in this assay.

CLAIMS

1. A compound of formula (I):



5

(I)

in which :

one of X and Y is N and the other is CH;

Z represents oxygen or sulphur;

- 10 R^1 represents (C_{1-6}) alkyl, (C_{2-6}) alkenyl or (C_{1-6}) alkoxy, any of which may be optionally substituted; halogen, R^7CO- or NR^8R^9CO- ;

- 15 R^2 , R^3 , R^4 , R^5 and R^6 independently represent (C_{1-6}) alkyl, (C_{2-6}) alkenyl, (C_{1-6}) alkoxy or (C_{1-6}) alkylthio, any of which may be optionally substituted; hydrogen, halogen, nitro, cyano, aryloxy, aryl (C_{1-6}) alkyloxy, aryl (C_{1-6}) alkyl, R^7CO- , R^7SO_2NH- , $R^7CON(R^{10})-$, NR^8R^9- , NR^8R^9CO- , $-COOR^8$, heterocyclyl or heterocyclyl (C_{1-6}) alkyl; or an adjacent pair of R^2 , R^3 , R^4 , R^5 and R^6 together with the carbon atoms to which they are attached form an optionally substituted carbocyclic or heterocyclic ring;

R^7 is (C_{1-6}) alkyl or aryl;

R^8 and R^9 independently represent hydrogen, (C_{1-6}) alkyl, aryl or aryl (C_{1-6}) alkyl;

R^{10} is hydrogen or (C_{1-6}) alkyl; and

- 20 n is 0, 1, 2 or 3;


or a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1 in which X is N and Y is CH.


- 25 3. A compound according to claim 1 or 2 in which Z represents oxygen.

4. A compound according to any one of the preceding claims in which n is 0 or 1.

5. A compound according to any one of the preceding claims in which R^2 to R^6 independently represent hydrogen, halogen, (C_{1-6}) alkoxy, (C_{1-6}) alkylthio or NR^8R^9 , and at least one of R^2 to R^6 is other than hydrogen; or an adjacent pair of R^2 to R^6 together with the carbon atoms to which they are attached form an optionally substituted 5- to 7-membered heterocyclic ring.
6. A compound according to any one of the preceding claims in which R^2 , R^5 and R^6 represent hydrogen, or R^2 , R^5 and R^6 represent hydrogen.
7. A process for the preparation of a compound of formula (I) as defined in any one of the preceding claims or a salt thereof which comprises coupling a compound of formula (II):




- with a compound of formula (III):



- wherein A and B are appropriate functional groups to form the -NHCONH- or -NHCSNH- moiety when coupled; n, X and Y are as defined in formula (I); and R^1 to R^6 are R^1 to R^6 as defined in formula (I) or groups convertible thereto; and thereafter optionally and as necessary and in any appropriate order, converting any R^1 to R^6 when other than R^1 to R^6 respectively to R^1 to R^6 , and/or forming a pharmaceutically acceptable salt.

8. A compound of formula (II):



(II)

wherein A is $-\text{CON}_3$, $-\text{NH}_2$, $-\text{CO}_2\text{H}$, $-\text{N}=\text{C}=\text{O}$, $-\text{N}=\text{C}=\text{S}$, $-\text{NHCOL}$, $-\text{NHCONH}_2$ or halogen; L is a leaving group; n, X and Y are as defined in formula (I); and R' is R'
 5 as defined in formula (I) or a group convertible thereto.

9. A pharmaceutical composition comprising a compound of formula (I) as defined in any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

10

10. A method of treating or preventing diseases or disorders where an antagonist of a human orexin receptor is required, which comprises administering to a subject in need thereof an effective amount of a compound of formula (I) as defined in any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof.

INTERNATIONAL SEARCH REPORT

International Application No

PC1/EP 99/03100

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D471/04 A61K31/44 //(C07D471/04,221:00,221:00)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	CA 2 222 687 A (SUMITOMO PHARMACEUTICALS CO., LTD.) 5 December 1996 (1996-12-05) the whole document	1,9
X	WO 86 06718 A (THE AUSTRALIAN NATIONAL UNIVERSITY) 20 November 1986 (1986-11-20) page 12, example 10; claim 10	8
X	WO 97 44337 A (CHIROSCIENCE LTD.) 27 November 1997 (1997-11-27) page 32, line 3	8
X	WO 92 22533 A (THE UPJOHN CO.) 23 December 1992 (1992-12-23) page 24, lines 22-32, page 26, lines 3-17	8
	-/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"Δ" document member of the same patent family

Date of the actual completion of the international search

9 September 1999

Date of mailing of the international search report

24/09/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Beslier, L

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 99/03100

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>POMORSKI J ET AL: "Ring transformations. XXXI. Didehydrohetarenes. XXIX. Reactivity of derivatives of 3-bromo-1,5-naphthyridine and 3-bromoquinoline towards potassium amide in liquid ammonia"</p> <p>RECL. TRAV. CHIM. PAYS-BAS (RTCPA3);1973; VOL.92 (9-10); PP.970-6, XP002114650</p> <p>Agric. Univ.;Lab. Org. Chem.; Wageningen; Neth.</p> <p>page 975, compound 18</p>	8
X	<p>VAN DEN HAAK H J W ET AL: "Hetarynes. Part XL. The amination of 3-bromo-2-ethoxy-1,5-naphthyridine. A reinvestigation"</p> <p>RECL. TRAV. CHIM. PAYS-BAS (RTCPA3,0034186X);1980; VOL.99 (3); PP.83-6, XP002114651</p> <p>Agric. Univ.;Dep. Org. Chem.; Wageningen; Neth.</p> <p>page 84, compound 22</p>	8
X	<p>POKORNY D J ET AL: "Naphthyridine chemistry. XV. Meisenheimer reaction of 1,6-naphthyridine 1,6-dioxide"</p> <p>J. HETEROCYCL. CHEM. (JHTCAD);1972; VOL.9 (5); PP.1151-3, XP002114652</p> <p>Ohio Univ.;Dep. Chem.; Athens; Ohio</p> <p>page 1151, compound 6</p>	8
X	<p>BARLIN G B ET AL: "Potential antimalarials. XIX. Syntheses and testing of.alpha.-(piperidin-2-yl)-.alpha.-(7'-tri fluoromethylquinolin-4'-yl)methanol and.alpha.-(7-bromo-1,5-naphthyridin-4-yl)-.alpha.-(piperidin-2'-yl)methanol"</p> <p>AUST. J. CHEM. (AJCHAS,00049425);1993; VOL.46 (11); PP.1695-703, XP002114653</p> <p>Aust. Natl. Univ.;John Curtin Sch. Med. Res.; Canberra; 2601; Australia (AU)</p> <p>page 1699, paragraph 1</p>	8
X	<p>WOZNIAK M ET AL: "Amination and synthesis of some nitronaphthyridines"</p> <p>LIEBIGS ANN. CHEM. (LACHDL,01702041);1993; (5); PP.471-5, XP002114654</p> <p>Cracow Tech. Univ.;Inst. Org. Chem. Technol.; Krakow; 31155; Pol. (PL)</p> <p>page 474, left-hand column, last paragraph</p>	8

-/--

INTERNATIONAL SEARCH REPORT

International Application No

PCI/EP 99/03100

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	BROWN E V ET AL: "Meisenheimer reaction in the 1,5-naphthyridine series. II" J. ORG. CHEM. (JOCEAH);1971; VOL.36 (10); PP.1331-5, XP002114655 Univ. Kentucky;Dep. Chem.; Lexington; Ky. page 1332, table II ---	8
X	MCCAUSTLAND D J ET AL: "1,5-Naphthyridines. Synthesis of 7-chloro-4-(4-diethylamino-1-methylbutylamino)-2-methoxy-1,5-naphthyridine and related compounds" J. HETEROCYCL. CHEM. (JHTCAD);1970; VOL.7 (3); PP.467-73, XP002114656 Midwest Res. Inst.;Kansas City; Mo. compounds V, VII, XIV, XVI and XXI ---	8
X	CHEMICAL ABSTRACTS, vol. 092, no. 9, 3 March 1980 (1980-03-03) Columbus, Ohio, US; abstract no. 076357, CZUBA W ET AL: "Reactions of some naphthyridones with phosphorus oxybromide" XP002114657 abstract & ZESZ. NAUK. UNIW. JAGIELLON., PR. CHEM. (ZUJCAQ,03730166);1979; VOL.24,; PP.13-20, Tech. Univ.;Inst. Org. Chem. Technol.; Krakow; Pol. ---	8
X	CHEMICAL ABSTRACTS, vol. 084, no. 17, 26 April 1976 (1976-04-26) Columbus, Ohio, US; abstract no. 120688, CZUBA W ET AL: "NMR characterization of 1,6-, 1,7- and 1,8-naphthyridine derivatives" XP002114658 abstract & UNIW. ADAMA MICKIEWICZA POZNANIU, WYDZ. MAT., FIZ. CHEM., 'PR.', SER. CHEM. (UAMPAL);1975; VOL.18,; PP.105-12, Krakow Tech. Univ.;Inst. Org. Chem. Technol.; Krakow; Pol. ---	8
	--- -/--	

INTERNATIONAL SEARCH REPORT

International Application No

PC1/EP 99/03100

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CHEMICAL ABSTRACTS, vol. 095, no. 23, 7 December 1981 (1981-12-07) Columbus, Ohio, US; abstract no. 203788, TITKOVA R M ET AL: "Synthesis and properties of 4-substituted 1,5-naphthyridines and their N-oxides" XP002114659 abstract & KHIM. GETEROTSIKL. SOEDIN. (KGSSAQ,04538234);1981; (6); PP.792-9, Vses. Nauchno-Issled. Khim.-Farm. Inst.;Moscow; 119021; USSR ---	8
X	CHEMICAL ABSTRACTS, vol. 117, no. 5, 3 August 1992 (1992-08-03) Columbus, Ohio, US; abstract no. 048378, CZUBA W ET AL: "Reactions of 1,5- and 1,8-naphthyridine 1-oxides with phosphorus oxide tribromide" XP002114660 abstract & UNIV. IAGELLON. ACTA CHIM. (UIACEG);1991; VOL.35,; PP.63-72, Tech. Univ.;Inst. Org. Phys. Chem.; Wroclaw; 50-370; Pol. (PL) ---	8
X	CHEMICAL ABSTRACTS, vol. 101, no. 11, 10 September 1984 (1984-09-10) Columbus, Ohio, US; abstract no. 090797, WOZNIAK M ET AL: "The syntheses of 4-amino-3-bromo-1,X-naphthyridines (X = 5, 6 and 7)" XP002114661 abstract & POL. J. CHEM. (PJCHDQ);1983; VOL.57 (4-5-6); PP.587-92, Polytech. Univ.;Inst. Org. Chem. Technol.; Krakow; 31155; Pol. (PL) ---	8
X	CHEMICAL ABSTRACTS, vol. 080, no. 17, 29 April 1974 (1974-04-29) Columbus, Ohio, US; abstract no. 095783, POMORSKI J ET AL: "Gas-phase bromination of 1,5-naphthyridine" XP002114662 abstract & ROCZ. CHEM. (ROCHAC);1973; VOL.47 (11); PP.2123-5, Pol. Acad. Sci.;Inst. Immunol. Exp. Ther.; Wroclaw; Pol. ---	8

-/--

INTERNATIONAL SEARCH REPORT

Inter: onal Application No
PC1/EP 99/03100

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,A	WO 99 09024 A (SMITHKLINE BEECHAM PLC) 25 February 1999 (1999-02-25) cited in the application the whole document -----	1,9,10

INTERNATIONAL SEARCH REPORT

I national application No. .

PCT/EP 99/ 03100

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim(s) 10
is(are) directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PC1/EP 99/03100

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
CA 2222687	A	05-12-1996	AU 699091 B	19-11-1998
			AU 5780896 A	18-12-1996
			CN 1191536 A	26-08-1998
			EP 0842933 A	20-05-1998
			WO 9638445 A	05-12-1996
			JP 9048780 A	18-02-1997
			US 5843957 A	01-12-1988
WO 8606718	A	20-11-1986	AU 5954886 A	04-12-1986
			EP 0222839 A	27-05-1987
			JP 63500173 T	21-01-1988
WO 9744337	A	27-11-1997	AU 697976 B	22-10-1998
			AU 1038697 A	27-06-1997
			AU 2906097 A	09-12-1997
			CA 2238376 A	12-06-1997
			CN 1208411 A	17-02-1999
			CN 1219171 A	09-06-1999
			CZ 9801714 A	14-10-1998
			CZ 9803719 A	17-03-1999
			EP 0873331 A	28-10-1998
			EP 0901482 A	17-03-1999
			WO 9720833 A	12-06-1997
			NO 982570 A	04-08-1998
			NO 985375 A	19-11-1998
			PL 327181 A	23-11-1998
			PL 329912 A	26-04-1999
			US 5773467 A	30-06-1998
			US 5925636 A	20-07-1999
WO 9222533	A	23-12-1992	AU 2157192 A	12-01-1993
			JP 5213884 A	24-08-1993
			MX 9202839 A	01-02-1993
WO 9909024	A	25-02-1999	AU 8741198 A	08-03-1999